BP-C1 Monotherapy in Patients With Metastatic Breast Cancer Cancer: Estimation of Optimal Duration of Treatment
NCT03789019
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
29
Enrollment
INDUSTRY
Sponsor class
Conditions
Metastatic Breast Cancer
Stage IV Breast Cancer
Interventions
DRUG:
BP-C1
Sponsor
Meabco A/S
Collaborators
[object Object]
[object Object]